Humabs BioMed SA:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Humabs BioMed SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11183
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:16
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スイス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Humabs BioMed SA (Humabs), a subsidiary of Vir Biotechnology Inc, is an antibody therapeutics biotechnology company that discovers and develops human monoclonal antibodies. The company’s pipeline programs include Flu A virus, ebola virus, HBV, rabies virus, JCV, dengue, and others. It develops cellclone technologies, a proprietary platform that delivers a pipeline of human monoclonal antibodies, and demonstrates the antibodies effectiveness in both in-vivo and in-vitro. Humabs technology platform uses immortalized B cells or cultured plasma cells obtained from the blood or lymphoid organs of the donor. The company’s pipeline products are used in the treatment of cancer, inflammatory and infectious diseases. It partners with pharmaceutical companies, government agencies, academic institution, and universities. Humabs is headquartered in Bellinzona, Switzerland.

Humabs BioMed SA – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Humabs BioMed SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Humabs BioMed SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Humabs BioMed SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Humabs BioMed SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Humabs BioMed SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Humabs BioMed SA, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Agilvax Enters into Development Agreement with Humabs Biomed 10
Licensing Agreements 11
Humabs Biomed Enters into Licensing Agreement with MedImmune 11
Acquisition 12
Vir Biotechnology Acquires Humabs BioMed 12
Humabs BioMed SA – Key Competitors 13
Humabs BioMed SA – Key Employees 14
Humabs BioMed SA – Locations And Subsidiaries 15
Head Office 15
Appendix 16
Methodology 16
About GlobalData 16
Contact Us 16
Disclaimer 16

List of Tables
Humabs BioMed SA, Pharmaceuticals & Healthcare, Key Facts 2
Humabs BioMed SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Humabs BioMed SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Humabs BioMed SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Humabs BioMed SA, Deals By Therapy Area, 2012 to YTD 2018 8
Humabs BioMed SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Agilvax Enters into Development Agreement with Humabs Biomed 10
Humabs Biomed Enters into Licensing Agreement with MedImmune 11
Vir Biotechnology Acquires Humabs BioMed 12
Humabs BioMed SA, Key Competitors 13
Humabs BioMed SA, Key Employees 14

List of Figures
Humabs BioMed SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Humabs BioMed SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Humabs BioMed SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Humabs BioMed SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Humabs BioMed SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Humabs BioMed SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Humabs BioMed SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Humabs BioMed SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Humabs BioMed SA:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Knopp Biosciences LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary Knopp Biosciences LLC (Knopp Biosciences) is a drug discovery and development company that offers medicines for the treatment of inflammatory and neurological diseases. The company’s pipeline products include dexpramipexole and KCNQ2. Its dexpramipexole is an anti-inflammatory therapeutic fo …
  • Fluxys SA:企業の戦略的SWOT分析
    Fluxys SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Th …
  • XCyton Diagnostics Ltd-医療機器分野:企業M&A・提携分析
    Summary XCyton Diagnostics Ltd (Xcyton) is a molecular biology company that develops and markets diagnostics products and services. The company provides ELISA kit for the detection of HIV infection; ELISA products for the detection of Neurocysticercosis, Hepatitis C and Japanese encephalitis. It pro …
  • Explor Resources Inc.:企業のM&A・事業提携・投資動向
    Explor Resources Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Explor Resources Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M …
  • JX Nippon Oil & Energy Corporation-石油・ガス分野:企業M&A・提携分析
    Summary JX Nippon Oil & Energy Corporation (JXNOE) is a downstream refining company. The company refines and markets petroleum and petrochemical products. Its products include petrochemicals, lubricants, optical films, greases, fluids, engine oils, composites, Panaferd-AX, Tow PREPREG, sheet pallet …
  • Allianz Global Assistance SAS:企業の戦略・SWOT・財務情報
    Allianz Global Assistance SAS - Strategy, SWOT and Corporate Finance Report Summary Allianz Global Assistance SAS - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Vale SA:企業の戦略・SWOT・財務情報
    Vale SA - Strategy, SWOT and Corporate Finance Report Summary Vale SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • Smith & Nephew plc:企業の戦略・SWOT・財務分析
    Smith & Nephew plc - Strategy, SWOT and Corporate Finance Report Summary Smith & Nephew plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Investors Heritage Capital Corporation:企業の戦略・SWOT・財務情報
    Investors Heritage Capital Corporation - Strategy, SWOT and Corporate Finance Report Summary Investors Heritage Capital Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT ana …
  • GR. Sarantis S.A.:企業の戦略・SWOT・財務情報
    GR. Sarantis S.A. - Strategy, SWOT and Corporate Finance Report Summary GR. Sarantis S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Viscom AG (V6C):企業の財務・戦略的SWOT分析
    Viscom AG (V6C) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Cerner Corp (CERN):医療機器:M&Aディール及び事業提携情報
    Summary Cerner Corp (Cerner) is a provider of healthcare information technology and related services. It offers a comprehensive range of solutions and services which assist the clinical, financial and operational needs of organizations. The company’s major solutions include extended care solutions; …
  • Kering SA:戦略・SWOT・企業財務分析
    Kering SA - Strategy, SWOT and Corporate Finance Report Summary Kering SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • American Caresource Holdings Inc (GNOW)-製薬・医療分野:企業M&A・提携分析
    Summary American Caresource Holdings Inc (ACS) is a healthcare service provider that offers urgent and primary care services. The center’s services include urgent care, veterans care, primary care, and occupational health services. Its urgent care services offer treatment for chest pain, abdominal p …
  • Ardian Holding SAS:企業の戦略的SWOT分析
    Ardian Holding SAS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Ultrapar Participacoes S.A.:企業の戦略・SWOT・財務情報
    Ultrapar Participacoes S.A. - Strategy, SWOT and Corporate Finance Report Summary Ultrapar Participacoes S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • PT Hexindo Adiperkasa Tbk:企業の戦略・SWOT・財務分析
    PT Hexindo Adiperkasa Tbk - Strategy, SWOT and Corporate Finance Report Summary PT Hexindo Adiperkasa Tbk - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • NetSol Technologies, Inc. (NTWK):企業の財務・戦略的SWOT分析
    NetSol Technologies, Inc. (NTWK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Mercury NZ:企業の戦略・SWOT・財務情報
    Mercury NZ - Strategy, SWOT and Corporate Finance Report Summary Mercury NZ - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • RegeneRx Biopharmaceuticals Inc (RGRX):企業の財務・戦略的SWOT分析
    Summary RegeneRx Biopharmaceuticals Inc (RegeneRx) is a clinical-stage biopharmaceutical company that designs, researches and develops novel peptides targeted at diseases with unmet medical needs. The company offers clinical trials, science and discovery and business development services. Its busine …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆